Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis

May T, Bernardini M, Lheureux S, Aben KK, Bandera EV, Beckmann M, Benitez J, Berchuck A, Bjørge L, Carney ME, Cramer DW, Defazio A, Dörk T, Eccles DM, Friedlander M, García MJ, Goode EL, Hein A, Jensen A, Johnatty S, Kennedy CJ, Kiemeney LA, Kjær SK, Kupryjanczyk J, Matsuo K, McGuire V, Modugno F, Paddock LE, Pejovic T, Phelan CM, Riggan MJ, Rodriguez-Antona C, Rothstein JH, Sieh W, Song H, Terry KL, Altena AM, Vanderstichele A, Vergote I, Thomsen LCV, Webb PM, Wentzensen N, Wilkens LR, Ziogas A, Jiang H, Tone A (2023)

Publication Type: Journal article

Publication year: 2023

Journal

Book Volume: 66

Pages Range: E310-E320

Journal Issue: 3

DOI: 10.1503/cjs.017020

Abstract

Background: Women with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium to identify factors that affect survival in LGSC. Methods: We performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan-Meier survival curves. Results: Of the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients' median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage. Conclusion: This multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice.

Authors with CRIS profile

Additional Organisation(s)

Involved external institutions

Princess Margaret Cancer Centre / Princess Margaret Hospital Canada (CA) Spanish National Cancer Research Centre / Centro Nacional de Investigaciones Oncológicas (CNIO) Spain (ES) Haukeland University Hospital / Haukeland universitetssykehus Norway (NO) University of Hawaii (U.H.) United States (USA) (US) University of Sydney (USYD) Australia (AU) University of Southampton United Kingdom (GB) Prince of Wales Hospital (POWH) Australia (AU) Mayo Clinic United States (USA) (US) Kræftens Bekæmpelse Denmark (DK) QIMR Berghofer Medical Research Institute (früher: the Queensland Institute of Medical Research) Australia (AU) Radboud University Nijmegen Medical Centre / Radboudumc of voluit Radboud Universitair Medisch Centrum (UMC) Netherlands (NL) Stanford University United States (USA) (US) Aichi Cancer Center Research Institute Japan (JP) Westmead Hospital Australia (AU) UPMC Hillman Cancer Center United States (USA) (US) New Jersey, Department of Health United States (USA) (US) Oregon Health and Science University (OSHU) United States (USA) (US) H. Lee Moffitt Cancer Center & Research Institute United States (USA) (US) Duke University United States (USA) (US) Icahn School of Medicine at Mount Sinai United States (USA) (US) University of Cambridge United Kingdom (GB) Brigham and Women's Hospital (BWH) United States (USA) (US) Katholieke Universiteit Leuven (KUL) / Catholic University of Leuven Belgium (BE) National Cancer Institute (NCI) United States (USA) (US) University of California Irvine United States (USA) (US) Rutgers Cancer Institute of New Jersey United States (USA) (US) Medizinische Hochschule Hannover (MHH) / Hannover Medical School Germany (DE)

How to cite

APA:

May, T., Bernardini, M., Lheureux, S., Aben, K.K., Bandera, E.V., Beckmann, M.,... Tone, A. (2023). Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis. Canadian Medical Association Journal, 66(3), E310-E320. https://doi.org/10.1503/cjs.017020

MLA:

May, Taymaa, et al. "Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis." Canadian Medical Association Journal 66.3 (2023): E310-E320.

BibTeX: Download